REMINDER: Our user survey closes on Friday, please submit your responses here.
Yes it looks like an exciting new venture. Hopefully the presentation clarifies more on the funding and timeline for lab work. The 'ventures' page of the SRI website implies that SRI provide lab funding in exchange for modest equity on any successful product. If that's the case it sounds like a good deal to me. SRI obviously think that Nuvec has potential to optimise their own MGS product.
You would assume that SRI are not going to waste their time partnering with a company / product unless it has a certain degree of potential for commercial success. SRI clearly like what they see with Nuvec.
It is currently difficult for N4 to showcase their product to 'big pharma' so this collaboration should make it much easier to do so.
Sounds like a great step forward for N4P.
It was a press release of the article that has been doing the rounds of late:
https://www.ophthalmologytimes.com/view/n4-pharma-moving-novel-delivery-systems-towards-commercialization
“Non-viral, non-lipid delivery systems are in high demand in the exciting gene therapy and oncology spaces and we now have two such delivery systems,” Nigel Theobald, CEO of N4 Pharma, said in the company’s news release. “Nuvec continues to show its versatility as a novel delivery system and with LipTide we are developing our first commercial product which we are aiming to take into phase 1 clinical trials.”
'The company will now engage in discussions with the FDA and MHRA to approve a GLP toxicity study and first in human clinical trials.'